tirzepatide semaglutide efficacy side effects vs Semaglutide: A Comprehensive Comparison for Weight Loss Tirzepatide Side Effects Cancer: Evidence

Tirzepatide (same active ingredient as Mounjaro and Zepbound ) has become a sought after treatment of choice after results reported 15% to 18% weight loss findings during clinical trials (very similarly to Semaglutide)

Retatrutide will likely be a breakthrough for these people once it's approved

If youre currently taking liraglutide and considering your options, or youre comparing these medications for the first time, this guide covers the clinical evidence, side effects, practical differences, and cost to help you make an informed decision

With the launch of @EliLillyandCo 's orforglipron (Foundayo) for #obesity, many clinicians are asking how to switch patients who are already on a #GLP1 like semaglutide: Evidence-informed TLDR: semaglutide 1.5-2.0 mg/wk orforglipron max dose for #weightloss If switching from sema 2.4 mg/wk, start orforglipron 9 mg/d one week after the last injection, increase to 14.5 mg in 4 weeks, then increase to 17.2 mg, assuming tolerability Counsel that 5% of weight lost may be regained with this switch for details: 1/ With the launch of @EliLillyandCo 's orforglipron (Foundayo) for #obesity, many clinicians are asking how to switch patients who are already on a #GLP1 like semaglutide: Evidence-informed TLDR: semaglutide 1.5-2.0 mg/wk orforglipron max dose for #weightloss If switching from sema 2.4 mg/wk, start orforglipron 9 mg/d one week after the last injection, increase to 14.5 mg in 4 weeks, then increase to 17.2 mg, assuming tolerability Counsel that 5% of weight lost may be regained with this switch for details: 1/ 2/ If a patient is on semaglutide inj, therapeutic equivalence could be informed by its phase 2 trial (thelancet.com/journals/lance), where sema 0.2-0.3 mg/d (1.4-2.1 mg/wk) resulted in ~11% #weightloss at 52 weeks3/ This 11.2-11.6^% weight loss is similar to the 11.2% #weightloss at 72 weeks in ATTAIN-1 with oforglipron 36 mg/d (nejm.org/doi/full/10.10)4/ If you want to switch from sema 2.4 mg/wk to orforglipron, the ATTAIN-MAINTAIN protocol offers a reasonable starting point: Sema 2.4 mg/wk orforglipron 12 mg (9 mg) x 4 wks 24 mg (14.5 mg) x 4 wks 36 mg (17.2 mg) Remember that available doses on the market are a5/5 Read the package insert for additional information: pi.lilly.com/us/foundayo-us And my orforglipron prescribing 101 at @Medscape medscape.com/viewarticle/pr It would be easier, have fewer side effects, and more efficacy just to prescribe them oral Wegovy Join the conversation

RODRIGUEZ J

Possible side effects associated with Mounjaro (tirzepatide) may include nausea, vomiting, diarrhea, constipation, decreased appetite, or fatigue, particularly during dose adjustments